Gilead Sciences annual ebitda margin
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences EBITDA Margin Growth & History (GILD)
Gilead Sciences's ebitda margin was 43.45% for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 43.45% | +27.99 pp |
| 2024 | 2024-12-31 | 15.45% | −22.38 pp |
| 2023 | 2023-12-31 | 37.83% | +3.18 pp |
| 2022 | 2022-12-31 | 34.65% | −9.10 pp |
| 2021 | 2021-12-31 | 43.75% | +21.24 pp |
| 2020 | 2020-12-31 | 22.52% | +2.28 pp |
| 2019 | 2019-12-31 | 20.23% | −17.85 pp |
| 2018 | 2018-12-31 | 38.08% | −16.91 pp |
| 2017 | 2017-12-31 | 54.99% | −3.61 pp |
| 2016 | 2016-12-31 | 58.60% | −9.88 pp |
| 2015 | 2015-12-31 | 68.49% | +6.66 pp |
| 2014 | 2014-12-31 | 61.83% | +20.53 pp |
| 2013 | 2013-12-31 | 41.31% | −1.53 pp |
| 2012 | 2012-12-31 | 42.84% | −4.05 pp |
| 2011 | 2011-12-31 | 46.89% | −4.56 pp |
| 2010 | 2010-12-31 | 51.44% | +0.19 pp |
| 2009 | 2009-12-31 | 51.26% | +0.09 pp |
| 2008 | 2008-12-31 | 51.17% | −0.87 pp |
| 2007 | 2007-12-31 | 52.04% | — |
Gilead Sciences quarterly ebitda margin
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −131.95% | −168.20 pp |
| Q1 2026 | 2026-03-31 | 38.49% | +3.48 pp |
| Q4 2025 | 2025-12-31 | 56.45% | −8.90 pp |
| Q3 2025 | 2025-09-30 | 43.98% | +30.97 pp |
| Q2 2025 | 2025-06-30 | 36.25% | −3.18 pp |
| Q1 2025 | 2025-03-31 | 35.01% | +98.24 pp |
| Q4 2024 | 2024-12-31 | 65.36% | +33.58 pp |
| Q3 2024 | 2024-09-30 | 13.02% | −33.89 pp |
| Q2 2024 | 2024-06-30 | 39.43% | +3.88 pp |
| Q1 2024 | 2024-03-31 | −63.24% | −100.15 pp |
| Q4 2023 | 2023-12-31 | 31.78% | −6.31 pp |
| Q3 2023 | 2023-09-30 | 46.90% | −0.84 pp |
| Q2 2023 | 2023-06-30 | 35.55% | −5.25 pp |
| Q1 2023 | 2023-03-31 | 36.92% | +25.96 pp |
| Q4 2022 | 2022-12-31 | 38.10% | +18.03 pp |
| Q3 2022 | 2022-09-30 | 47.74% | −11.08 pp |
| Q2 2022 | 2022-06-30 | 40.80% | −3.68 pp |
| Q1 2022 | 2022-03-31 | 10.96% | −41.40 pp |
| Q4 2021 | 2021-12-31 | 20.07% | −21.51 pp |
| Q3 2021 | 2021-09-30 | 58.82% | +23.01 pp |
| Q2 2021 | 2021-06-30 | 44.47% | +95.67 pp |
| Q1 2021 | 2021-03-31 | 52.36% | +2.77 pp |
| Q4 2020 | 2020-12-31 | 41.58% | +36.58 pp |
| Q3 2020 | 2020-09-30 | 35.81% | +55.90 pp |
| Q2 2020 | 2020-06-30 | −51.20% | −100.06 pp |
| Q1 2020 | 2020-03-31 | 49.59% | +0.43 pp |
| Q4 2019 | 2019-12-31 | 5.00% | −0.16 pp |
| Q3 2019 | 2019-09-30 | −20.09% | −73.36 pp |
| Q2 2019 | 2019-06-30 | 48.87% | +2.19 pp |
| Q1 2019 | 2019-03-31 | 49.16% | −0.17 pp |
| Q4 2018 | 2018-12-31 | 5.16% | −34.66 pp |
| Q3 2018 | 2018-09-30 | 53.27% | −6.07 pp |
| Q2 2018 | 2018-06-30 | 46.67% | −13.66 pp |
| Q1 2018 | 2018-03-31 | 49.33% | −9.33 pp |
| Q4 2017 | 2017-12-31 | 39.82% | −16.09 pp |
| Q3 2017 | 2017-09-30 | 59.34% | +0.10 pp |
| Q2 2017 | 2017-06-30 | 60.33% | +1.42 pp |
| Q1 2017 | 2017-03-31 | 58.66% | −1.55 pp |
| Q4 2016 | 2016-12-31 | 55.92% | −10.70 pp |
| Q3 2016 | 2016-09-30 | 59.24% | −8.58 pp |
| Q2 2016 | 2016-06-30 | 58.91% | −9.67 pp |
| Q1 2016 | 2016-03-31 | 60.21% | −11.00 pp |
| Q4 2015 | 2015-12-31 | 66.61% | +6.99 pp |
| Q3 2015 | 2015-09-30 | 67.82% | +9.55 pp |
| Q2 2015 | 2015-06-30 | 68.58% | +0.63 pp |
| Q1 2015 | 2015-03-31 | 71.21% | +9.86 pp |
| Q4 2014 | 2014-12-31 | 59.63% | +21.77 pp |
| Q3 2014 | 2014-09-30 | 58.28% | +16.10 pp |
| Q2 2014 | 2014-06-30 | 67.96% | +24.54 pp |
| Q1 2014 | 2014-03-31 | 61.35% | +19.06 pp |
| Q4 2013 | 2013-12-31 | 37.85% | −6.39 pp |
| Q3 2013 | 2013-09-30 | 42.18% | −2.34 pp |
| Q2 2013 | 2013-06-30 | 43.41% | −2.12 pp |
| Q1 2013 | 2013-03-31 | 42.29% | +5.68 pp |
| Q4 2012 | 2012-12-31 | 44.25% | +2.38 pp |
| Q3 2012 | 2012-09-30 | 44.52% | −4.42 pp |
| Q2 2012 | 2012-06-30 | 45.53% | −3.68 pp |
| Q1 2012 | 2012-03-31 | 36.61% | −11.16 pp |
| Q4 2011 | 2011-12-31 | 41.87% | −3.52 pp |
| Q3 2011 | 2011-09-30 | 48.94% | −2.42 pp |
| Q2 2011 | 2011-06-30 | 49.22% | −3.12 pp |
| Q1 2011 | 2011-03-31 | 47.78% | −8.73 pp |
| Q4 2010 | 2010-12-31 | 45.39% | −8.03 pp |
| Q3 2010 | 2010-09-30 | 51.35% | +0.84 pp |
| Q2 2010 | 2010-06-30 | 52.33% | +5.21 pp |
| Q1 2010 | 2010-03-31 | 56.51% | +2.79 pp |
| Q4 2009 | 2009-12-31 | 53.42% | — |
| Q3 2009 | 2009-09-30 | 50.51% | −1.09 pp |
| Q2 2009 | 2009-06-30 | 47.12% | — |
| Q1 2009 | 2009-03-31 | 53.71% | — |
| Q3 2008 | 2008-09-30 | 51.60% | — |
Gilead Sciences ebitda margin trends
Over the last five fiscal years, Gilead Sciences's ebitda margin increased from 22.52% to 43.45%, a change of +20.93 percentage points. The latest reported quarter, Q2 2026, shows −131.95%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
